In addition to its direct anti-tumor effect on BTK, ibrutinib irreversibly binds ITK (Interleukin-2 inducible kinase) and inhibits downstream activation of Th2 cells after TCR stimulation both in vitro and in vivo [31]. This evidence concerns the gene ITK and neoplasm.